Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Study to Assess the Potential Effects of Itraconazole (a Strong CYP3A4 Inhibitor) on the Pharmacokinetics of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-Label, Multicenter Study to Assess the Potential Effects of Itraconazole (a Strong CYP3A4 Inhibitor) on the Pharmacokinetics of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary) ; Lurbinectedin (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors PharmaMar

    • Most Recent Events

    • 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Status changed from recruiting to completed, according to Results presented at the 48th European Society for Medical Oncology Congress.
    • 16 Oct 2023 According to a Jazz Pharmaceuticals plc media release, clinical data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place in Madrid, Spain, from October 20-24, 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top